BR112015026286A2 - angiotensinas na distrofia muscular - Google Patents
angiotensinas na distrofia muscularInfo
- Publication number
- BR112015026286A2 BR112015026286A2 BR112015026286A BR112015026286A BR112015026286A2 BR 112015026286 A2 BR112015026286 A2 BR 112015026286A2 BR 112015026286 A BR112015026286 A BR 112015026286A BR 112015026286 A BR112015026286 A BR 112015026286A BR 112015026286 A2 BR112015026286 A2 BR 112015026286A2
- Authority
- BR
- Brazil
- Prior art keywords
- muscular dystrophy
- angiotensin
- peptide
- present
- val3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
resumo patente de invenção: "angiotensinas na distrofia muscular". a presente invenção refere-se, entre outros, a métodos, para tratar distrofia muscular, incluindo administrar a um indivíduo que sofre ou é suscetível a uma distrofia muscular um peptídeo angiotensina (1-7). a presente invenção fundamenta-se, em parte, na descoberta inesperada de que a administração de um peptídeo angiotensina (1-7) em um modelo animal de distrofia muscular reduz a fibrose, recupera a atividade locomotora e restaura o equilíbrio simpático-vagal, os quais são sintomas característicos em pacientes que sofrem de distrofia muscular. assim, a presente invenção provê uma nova terapia mais eficaz para distrofia muscular. em algumas modalidades, um peptídeo angiotensina (1-7) inclui a sequência natural de aminoácidos da angiotensina (1-7), asp1-arg2-val3-tyr4-ile5-his6-pro-7 (seq id no:1). em algumas modalidades, o peptídeo angiotensina (1-7) é um equivalente funcional da seq id no:1. em algumas modalidades, o peptídeo linear possui uma sequência de aminoácidos igual a asp1-arg2-val3-ser4-h'is5-cys7 (seq id no:2). em algumas modalidades, o peptídeo cíclico é uma angiotensina (1-7) 4,7-ciclizada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361813929P | 2013-04-19 | 2013-04-19 | |
| US201361818307P | 2013-05-01 | 2013-05-01 | |
| PCT/US2014/034615 WO2014189634A1 (en) | 2013-04-19 | 2014-04-18 | Angiotensins in muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015026286A2 true BR112015026286A2 (pt) | 2017-10-10 |
Family
ID=51933952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015026286A BR112015026286A2 (pt) | 2013-04-19 | 2014-04-18 | angiotensinas na distrofia muscular |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160074464A1 (pt) |
| EP (1) | EP2986341A4 (pt) |
| JP (1) | JP2016522178A (pt) |
| KR (1) | KR20160026855A (pt) |
| CN (1) | CN105636645A (pt) |
| AU (1) | AU2014269028A1 (pt) |
| BR (1) | BR112015026286A2 (pt) |
| CA (1) | CA2909002A1 (pt) |
| MX (1) | MX2015014668A (pt) |
| RU (1) | RU2015141336A (pt) |
| WO (1) | WO2014189634A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9943509B2 (en) | 2013-03-15 | 2018-04-17 | University Of Southern California | Methods, compounds, and compositions for the treatment of musculoskeletal diseases |
| US10973869B2 (en) | 2017-05-17 | 2021-04-13 | Constant Therapeutics Llc | Methods of treating cardiomyopathy associated with genetic disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| ES2454741T3 (es) * | 2007-01-26 | 2014-04-11 | Universidade Federal De Minas Gerais - Ufmg | Composiciones farmac�uticas y m�todos para tratar la disfunci�n er�ctil |
| EP2163259B1 (en) * | 2008-09-12 | 2012-06-13 | Charité-Universitätsmedizin Berlin (Charité) | Use of an Ang-(1-7) receptor agonist in acute lung injury |
| US9474689B2 (en) * | 2011-10-25 | 2016-10-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| BR132012028005E2 (pt) * | 2012-10-31 | 2014-11-18 | Univ Minas Gerais | Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares. |
-
2014
- 2014-04-18 RU RU2015141336A patent/RU2015141336A/ru not_active Application Discontinuation
- 2014-04-18 CA CA2909002A patent/CA2909002A1/en not_active Abandoned
- 2014-04-18 AU AU2014269028A patent/AU2014269028A1/en not_active Abandoned
- 2014-04-18 EP EP14800597.8A patent/EP2986341A4/en not_active Withdrawn
- 2014-04-18 JP JP2016509119A patent/JP2016522178A/ja active Pending
- 2014-04-18 KR KR1020157032700A patent/KR20160026855A/ko not_active Application Discontinuation
- 2014-04-18 BR BR112015026286A patent/BR112015026286A2/pt not_active Application Discontinuation
- 2014-04-18 MX MX2015014668A patent/MX2015014668A/es unknown
- 2014-04-18 WO PCT/US2014/034615 patent/WO2014189634A1/en active Application Filing
- 2014-04-18 US US14/785,538 patent/US20160074464A1/en not_active Abandoned
- 2014-04-18 CN CN201480034275.5A patent/CN105636645A/zh active Pending
-
2017
- 2017-09-05 US US15/695,731 patent/US20180221433A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015141336A (ru) | 2017-05-22 |
| CN105636645A (zh) | 2016-06-01 |
| EP2986341A1 (en) | 2016-02-24 |
| US20160074464A1 (en) | 2016-03-17 |
| WO2014189634A1 (en) | 2014-11-27 |
| US20180221433A1 (en) | 2018-08-09 |
| EP2986341A4 (en) | 2016-11-30 |
| KR20160026855A (ko) | 2016-03-09 |
| JP2016522178A (ja) | 2016-07-28 |
| MX2015014668A (es) | 2016-06-30 |
| AU2014269028A1 (en) | 2015-10-22 |
| CA2909002A1 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ713202A (en) | Diagnosis and treatments relating to th2 inhibition | |
| CY1118517T1 (el) | Πνευμονικη χορηγηση για λεβοντοπα | |
| NZ598348A (en) | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels | |
| PH12020500555A1 (en) | Esketamine for the treatment of depression | |
| BR112012024934A2 (pt) | sistemas de ablação de transgene induzida farmacologicamente | |
| JP2015517488A5 (pt) | ||
| JP2012041342A5 (pt) | ||
| JP2018509388A5 (pt) | ||
| BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| NZ602471A (en) | Antagonists of activin-actriia and uses for increasing red blood cell levels | |
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| JP2016508123A5 (pt) | ||
| IN2014DN06789A (pt) | ||
| MX2012010161A (es) | Metodo para tratar el mal de parkinson. | |
| NZ623576A (en) | Tfpi inhibitors and methods of use | |
| PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| BR112015010396A2 (pt) | terapia de combinação | |
| BR112014006587A2 (pt) | modulação antisense da expressão de gcgr | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| BR112014012460A2 (pt) | proteínas recombinantes e seus usos terapêuticos | |
| BR112013007423A2 (pt) | terapia combinada no que diz respeito ao tratamento da infecção por hcv | |
| BR112016013961A2 (pt) | angiotensina ii sozinha ou em combinação para o tratamento da hipotensão | |
| BR112013026698A2 (pt) | formulações do tipo tópica compreendendo depsipeptídeo cíclico | |
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
| EP2552462A4 (en) | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |